Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI
FDA meeting supports single pivotal Phase 3 clinical trial of SPR994 in cUTI SPR994 IND submitted and ADAPT-PO Phase 3 […]